# EphA2 receptor

Source: https://onco.cc/targets/epha2/  
OnCo record `epha2` (Target). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

EphA2 is a cell-guidance receptor that many solid tumours overexpress; dasatinib and regorafenib block it among their many kinase targets, and it is being tested as an antibody-drug conjugate and CAR-T target.

## Summary

Ephrin type-A receptor 2 helps cells read their neighbours' positions during development and is overexpressed in glioblastoma, ovarian, breast, lung and pancreatic cancers, where ligand-independent signalling promotes invasion. Dasatinib and regorafenib inhibit it as secondary targets. Antibody-drug conjugates and CAR-T cells against EphA2 have reached early trials, notably in glioblastoma.

## Fields

- Kind: Target
- Last checked: 2026-09-04
- Symbol: EPHA2
- Class: kinase
- Biology: A receptor tyrosine kinase for ephrin-A ligands; ligand binding suppresses growth signalling, while unliganded EphA2 phosphorylated by AKT drives motility.
- Where found: Glioblastoma, ovarian, breast, lung and pancreatic cancers (overexpressed); Low in normal adult epithelium

## Sources

- Wikipedia: https://en.wikipedia.org/wiki/EPH_receptor_A2
- UniProt P29317: EPHA2: https://www.uniprot.org/uniprotkb/P29317/entry
- HGNC:3386 EPHA2: https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:3386
- ChEMBL target CHEMBL2068: https://www.ebi.ac.uk/chembl/explore/target/CHEMBL2068

## Connected records

- cancers: [Glioma & glioblastoma](https://onco.cc/cancers/glioblastoma/), [Ovarian cancer](https://onco.cc/cancers/ovarian/)
- drugs: [Dasatinib](https://onco.cc/drugs/dasatinib/), [Regorafenib](https://onco.cc/drugs/regorafenib/)

---
JSON: https://onco.cc/api/v1/entities/epha2.json